Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Transplantation and Donation

Transplantation and Donation

Recruiting

Evaluating itolizumab to treat chronic graft-versus-host disease

The purpose of the study is to investigate the safety and efficacy of itolizumab versus placebo in individuals with acute graft-versus-host disease, when combined with corticosteroids as a first line treatment.

Status
Recruiting
Principal Investigator
Jennifer White
Body Locations and Systems
Immune System
Age
12 and above

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).

Status
Recruiting
Principal Investigator
Jagbir Gill
Body Locations and Systems
Kidney Transplantation
Area
Vancouver
Age
18 and above

Canadian-Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK)

Patients on the waiting list for kidney transplantation are at risk for coronary artery disease (CAD).  The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown. Currently patients without any symptoms of CAD undergo annual testing to determine if they have disease. This study will determine if screening is necessary.

Status
Recruiting
Principal Investigator
Jagbir Gill
Body Locations and Systems
Kidney Transplantation
Coronary Artery Disease
Area
Vancouver
Age
18 and above

A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf (Astellas)

While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation have not been achieved. The specific drug combination that provides the best outcomes with the least amount of side effects is not known. Each kidney transplant center uses the combination of drugs that they believe is optimal.

Status
Recruiting
Principal Investigator
Jagbir Gill
Body Locations and Systems
Kidney Transplantation
Area
Vancouver
Age
19 and above

Closed for Recruitment

Evaluating axatilimab to treat chronic graft-versus-host disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of axatilimab at three different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least two prior lines of systemic therapy.

Status
Closed for Recruitment
Principal Investigator
Jennifer White
Body Locations and Systems
Immune System
Age
2 and above

Kidney Transplant Failure

Primary Hypotheses:

Status
Closed for Recruitment
Body Locations and Systems
Kidney Transplantation
Dialysis
Kidney Failure
Area
Vancouver
Age
18 and above
Subscribe to Transplantation and Donation

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy